Author

Gowramma Byran

h-index 9 View on Semantic Scholar

We have 3 of 52 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Translational Horizons in Targeted Oncology: Mechanistic Insights, Therapeutic Innovations, and Clinical Impact.

INTRODUCTION Because of the elevated prevalence and death rates of cancers such as breast, lung, colorectal, bladder, gastrointestinal, and liver malignancies, cancer remains an important global health issue. More productive, targeted, and personalized therapeutic treatments are crucial, as evidenced by the growing loa...

Hardha Balachandran, Gowramma Byran, S. Murugesan et al. · Current Cancer Drug Targets · 0 citations

Sep 2026

Computational Identification of Shikimic Acid Derivatives as Potential SARS-CoV-2 Inhibitors: An In Silico Approach.

The docking, ADMET, and MD simulation studies indicate that the designed shikimic acid derivatives have good binding affinity and drug-like properties, and are stable in the active site of the SARS-CoV-2 main protease.

Hardha Balachandran, Kaviarasan Lakshmanan, Dipen Purohit et al. · Current Computer - Aided Dru... · 0 citations

Aug 2026

Design and Evaluation of Naphthoxy and Phenoxy amide as Potential PARP 1 inhibitors: Molecular Docking and In Vitro Analysis.

Overall, compound B2 emerged as a promising PARP1 inhibitor with strong binding affinity, structural stability, and significant in vitro anticancer activity, warranting further optimization and preclinical investigation.

Hardha Balachandran, Subhajit Majumder, Gowramma Byran et al. · Current Medicinal Chemistry · 0 citations